No products in the cart.
MODULE 6: THE ECONOMICS OF CARE: PHARMACOECONOMICS & PAYER STRATEGIES
Section 6.3: Step-Therapy and Utilization Review Protocols
Examining common payer strategies for managing drug utilization, understanding the clinical and economic rationale behind step-edits, prior authorizations (PAs), and quantity limits (QLs), and the pharmacist’s role in navigating them.
SECTION 6.3
Step-Therapy and Utilization Review Protocols
From Gatekeeper to Guide: Mastering the Art of Utilization Management.
6.3.1 The “Why”: Why Do These Barriers Exist?
As a practicing pharmacist, you are on the front lines of a daily battle. A patient presents a prescription. You submit the claim. The screen flashes red: REJECTED. REQUIRES PRIOR AUTHORIZATION. To you, your provider, and your patient, this is a barrier. It is a frustrating, time-consuming, and seemingly arbitrary hoop to jump through, one that delays care and creates administrative chaos. From your perspective, it feels like an adversarial system designed to say “no.”
The purpose of this masterclass section is to completely reframe that experience. We are going to move you from the front line of the battle to the “situation room” where the strategy is planned. You will learn that these “barriers” are not arbitrary at all. They are the direct, real-world implementation of the very economic principles we just learned in Sections 6.1 and 6.2.
Utilization Management (UM)—the formal term for these protocols—is the set of tools a payer (like an insurer or PBM) uses to manage the cost, quality, and appropriateness of healthcare services. It is the practical application of their pharmacoeconomic analyses.
- When a payer’s Cost-Effectiveness Analysis (CEA) determines that a new \$5,000/month drug offers only a tiny benefit over an existing \$50/month drug (a massive ICER), they implement Step-Therapy to ensure patients try the cost-effective option first.
- When a new \$500,000 gene therapy is launched, the payer’s Budget Impact Model (BIM) shows a catastrophic affordability problem. They implement a Prior Authorization (PA) to ensure that only the patients who meet the drug’s exact, on-label criteria can get it.
- When a new opioid hits the market, the payer implements a Quantity Limit (QL) to align with CDC safety guidelines and prevent abuse.
These tools are not just about saving money (though that is a primary driver). They are the central nervous system of a health plan, designed to enforce the “Triple Aim” of healthcare:
- Improve Patient Experience (Quality): By ensuring the patient is receiving a therapy that is safe, effective, and clinically appropriate for their specific diagnosis. A PA can be a safety net that stops a dangerous duplication or a sub-optimal choice.
- Improve the Health of Populations (Appropriateness): By steering the entire population of patients toward evidence-based, first-line therapies that have the best combination of safety and efficacy (e.g., generics and preferred brands).
- Reduce the Per-Capita Cost of Care (Cost): By managing affordability and steering away from therapies that offer poor “value” (i.e., those with unacceptably high ICERs).
Your role as a community pharmacist has often been that of the frustrated messenger. Your new role as an Advanced Specialty Pharmacist is that of the expert navigator and translator. You are not just a “gatekeeper”—a term you should reject. You are a guide. You understand why the gate is there, what the “password” is (i.e., the clinical criteria), and how to gather the evidence to prove your patient has it. This section is your playbook for mastering that art.
Pharmacist Analogy: The Corporate Travel Policy
Imagine you work for a large company (the “Health Plan”). Your job (your “health”) requires you to travel to a client in another city (you need “treatment”). You can’t just book any flight you want on the corporate credit card. You must follow the Corporate Travel Policy (the “Formulary and UM Rules”).
How the Policy Works:
1. The Formulary / Preferred List:
The policy states: “Employees must book on our preferred airlines (Delta or United), as we have a corporate contract with them.” (These are the “Preferred” / Tier 2 drugs).
2. Prior Authorization (PA):
The policy states: “All flights costing over \$1,000 require manager approval.” You find a \$1,200 non-stop flight on a non-preferred airline (the “Non-Preferred” / Tier 3 drug). To get it, you must submit a “Travel Exception Form” (a PA request) to your manager (the Payer). Your manager will ask: “Why can’t you take the \$400 flight on Delta?” Your justification—”This is the only non-stop flight, and it allows me to make the client dinner, which will secure the \$5 million contract”—is the clinical justification that gets the PA approved.
3. Step-Therapy (ST):
The policy states: “All employees must book ‘Main Cabin’ (Step 1 / Generic). Employees may only book ‘Business Class’ (Step 2 / Preferred Brand) if the flight is over 8 hours or if they have a documented medical need (e.g., a broken leg).” You, the specialty pharmacist, are the one who provides this documentation. You don’t just say, “My patient wants business class.” You say, “My patient’s ‘flight’ is 10 hours long; they meet the criteria for ‘Business Class’ per your own policy.”
4. Quantity Limit (QL):
The policy states: “The company will pay for one checked bag.” (This is the Quantity Limit). You need to bring three bags for a trade show (you need a higher dose). You must file an exception request (a QL Override) explaining why the standard limit is not appropriate for this specific, justified business need.
Your Role: The Expert Executive Assistant
A novice pharmacist is just the travel agent who says, “Sorry, the flight is denied.” An Advanced Specialty Pharmacist is the expert Executive Assistant. You know the travel policy inside and out. You know the manager’s preferences. You know exactly what justification is needed. You proactively gather the flight times, the client meeting schedule, and the doctor’s note for the broken leg, and you submit the “Travel Exception Form” perfectly the first time. You don’t just see the “rejection”; you see the “path to approval.”
6.3.2 Deep Dive: Prior Authorization (PA) — The “Permission Slip”
The Prior Authorization (PA), or “pre-certification,” is the most common UM tool. It is a “pause point” inserted into the claims process by a payer. It is a checkpoint that requires the prescriber (or their agent, like you) to obtain pre-approval from the payer before the pharmacy can dispense the medication and be reimbursed for it. When a claim is rejected for a PA, the payer is not saying “No.” They are saying, “Not yet. You need to tell us why.”
The Multifaceted Rationale for a PA
It’s a common misconception that PAs are only about cost. While cost is a major factor, PAs serve several distinct clinical, safety, and economic functions simultaneously.
Masterclass Table: The Four Functions of a Prior Authorization
| Function | Payer’s Rationale (“Why we do this”) | Drug Classes Commonly Targeted |
|---|---|---|
| 1. Cost Control & Affordability | To manage the Budget Impact of high-cost medications. This is a “gate” to ensure that an expensive drug is the only option, not just the easiest one. It creates a “friction” that encourages the use of cheaper alternatives. |
|
| 2. Clinical Appropriateness | To ensure the drug is being prescribed on-label and for the correct diagnosis. Payers only want to pay for uses that are evidence-based and FDA-approved (or compendia-supported). | |
| 3. Safety & Quality | To act as a critical safety checkpoint. The PA process can be used to verify that the patient is not on duplicate therapy, that the dose is appropriate, or that necessary monitoring is being done. |
|
| 4. Utilization Steering | To enforce the plan’s Formulary and Step-Therapy rules. The PA is the mechanism by which a Step-Therapy policy is enforced. It is the “lock” on the Step-2 drug. |
|
The PA Workflow: From Rejection to Resolution
As a specialty pharmacist, you are no longer a passive observer of this process. You are the active quarterback. Your high-touch service model depends on you owning this workflow. This is one of the single greatest services you provide to both patients and providers.
The Specialty Pharmacy PA Workflow
1. Prescription & Benefits Investigation
Specialty Pharmacy (SP) receives an electronic Rx for a high-cost drug. The intake team immediately runs a “test claim” or eligibility check.
2. The “Pause Point”: PA Identified
The claim rejects: “PA Required.” This is not a failure; it is the expected start of the process. The Rx is routed to the SP’s internal “PA Team.”
3. Initiation & Evidence Gathering
The PA Team pharmacist or technician logs into a PA portal (like CoverMyMeds, Surescripts, or the payer’s own portal). They find the specific question set for that drug and payer. The SP’s EMR may already have the patient’s diagnosis, but they often need chart notes. The SP faxes the provider a “PA Support” form, saying, “We are initiating the PA. Please send us the following 3 items…”
4. Building the Case & Submission
The provider’s office sends the chart notes, failed therapies, and relevant labs. The SP pharmacist *translates* these notes into a “bulletproof” argument, answering every question in the PA set with clear, concise, and documented evidence. The case is submitted electronically.
5. Payer Review
The case enters the payer’s queue. An “auto-adjudication” system might approve it if all fields match a pre-set logic. If not, it is routed to a human technician, then to a pharmacist, for manual review. This can take 24-72 hours (or longer, depending on state laws).
6A. DECISION: APPROVED
The payer sends an approval (with an authorization number and expiration date). The SP’s PA team links this auth to the Rx, re-bills the claim, and moves the Rx to the clinical pharmacist for final verification and patient counseling.
6B. DECISION: DENIED
The payer sends a denial notice with a specific reason. The SP pharmacist reviews the reason (e.g., “Step-therapy failure not documented”). The SP team then contacts the provider to initiate an Appeal or a Peer-to-Peer Review.
Tutorial: How to Win a Prior Authorization
This is one of the most valuable, practical skills you can develop. A well-constructed PA submission is an art form. It is the difference between a 24-hour approval and a 2-week cycle of denials and appeals. Your goal is to make it impossible for the reviewer to say no.
The Pharmacist’s “Bulletproof PA” Playbook
When you are initiating a PA, you are a lawyer building a case. You must prove your patient is “guilty” of meeting the criteria.
- 1. Become the “Portal Master”: Do not use a fax machine. Faxing is where PAs go to die. It’s a black hole. You must master the electronic portals: CoverMyMeds (CMM), Surescripts Prior Authorization, and the payer’s specific provider portal (e.g., Optum, CVS Caremark). Electronic submissions are trackable, faster, and often use automated logic for instant approvals.
- 2. Gather Your “Ammunition” (The 5 Essentials): Before you type a single word, have this information open on your screen:
- A. The Correct Diagnosis Code (ICD-10): “Psoriasis” is not good enough. “L40.0, Psoriasis vulgaris” is. This code is the first thing the system checks.
- B. The Patient’s Chart Notes (The “H&P”): You need the objective data. “Patient reports joint pain” is weak. “Patient has 12 tender/swollen joints” is strong.
- C. The Failed Therapies: This is the #1 reason for denial. You need the drug names, doses, dates of use, and the reason for failure. (e.g., “Methotrexate 20mg/wk, 01/2024-06/2024. Failed to control symptoms, DAS-28 score remains 5.2.”).
- D. Relevant Labs & Scores: For RA, you need a disease activity score (DAS-28, CDAI). For HLD, you need a baseline LDL. For Hepatitis, you need a genotype. For Asthma, you need an FEV1. You must provide the objective proof that the disease is severe enough.
- E. The Payer’s Specific Policy: This is the secret weapon. Go to the payer’s website and find the actual PDF of their “Medical Policy for [Drug Name].” This is their rulebook. It tells you exactly what they require. Your PA submission should simply be a checklist proving you meet all their stated rules.
- 3. Write for the Reviewer (Not for a Novel): The first person to see your PA is likely a technician or nurse with 60 seconds to review it. Do not paste a 10-page chart note. Write a concise, bulleted summary in the “Clinical Justification” box.
Masterclass Table: Building a “Bulletproof” PA Argument
Scenario: Request for Otezla (apremilast) for a patient with Psoriasis.
| PA Section | A “Weak” Argument (Will be Denied) | A “Bulletproof” Argument (Will be Approved) |
|---|---|---|
| Diagnosis | “Psoriasis” | “Moderate-to-severe plaque psoriasis (ICD-10: L40.0) with >10% Body Surface Area (BSA) involvement.” |
| Failed Therapies | “Patient tried creams.” | “Patient has documented trial AND failure of the following (per plan’s Step-Therapy policy):
1. Topical (Step 1): Clobetasol 0.05% cream. Used for 6 months (01/24-06/24). Failed to control plaques. 2. Systemic (Step 2): Methotrexate 15mg PO Qweek. Used for 4 months (06/24-10/24). Discontinued due to LFT elevation (AST 120).” |
| Clinical Justification | “Patient has moderate-to-severe plaque psoriasis (>10% BSA) and has failed first-line topical and systemic therapy. Per payer’s medical policy, patient is now eligible for a biologic/oral systemic agent. Patient has a contraindication to MTX (hepatotoxicity) and declines phototherapy due to work schedule. Otezla is the appropriate, indicated next-line agent.” | |
| Required Labs | (Left blank) | “Patient has a negative TB test (PPD) on 10/20/2025. Baseline LFTs WNL.” |
When You Are Denied: The Appeal and the “Peer-to-Peer”
Even a perfect PA can be denied by a low-level reviewer. The next step is the Appeal. This is where you, or the provider, get on the phone with a pharmacist or physician at the health plan. This is the “Peer-to-Peer” (P2P) review. This is not a fight; it is a professional consultation. You are one clinical expert speaking to another. Your goal is to use the “Bulletproof Argument” you built and walk them through it verbally.
Your Script: “Hi Dr. Smith, this is [Your Name], the specialty pharmacist for our mutual patient, Jane Doe. I’m calling about the Otezla denial. I’ve reviewed the chart and our submission, and it looks like the patient meets your plan’s criteria. I’m looking at your medical policy right now—it states patients need to fail a topical and a systemic, which she has. I can confirm a 6-month failure of Clobetasol and a 4-month trial of Methotrexate, which was stopped for hepatotoxicity. Her BSA is over 10%. Can you help me understand what was missing so we can get this approved for her?”
This collaborative, evidence-based approach has a much higher success rate than an angry, adversarial call.
6.3.3 Deep Dive: Step-Therapy (ST) — The “Try This First” Protocol
Step-Therapy (ST), also called “step-edits,” is one of the most common and clinically rational UM tools. As we’ve discussed, it is a specific type of PA. It is not a “wall”; it is a “staircase.” It is a pre-defined protocol that requires a patient to try one or more preferred medications (Step 1) before they are eligible to “step up” to a non-preferred medication (Step 2 or 3).
The Economic and Clinical Rationale for Step-Therapy
The rationale for ST is the direct implementation of the Cost-Effectiveness Analyses (CEAs) we learned about in Section 6.2.
The Payer’s Logic (A CEA in Action):
A new brand-name PPI (Proton Pump Inhibitor), “Newprazole,” is launched for \$400/month. The plan’s current preferred generic, Omeprazole, costs \$8/month.
- Efficacy Review ($\Delta E$): The plan’s P&T committee reviews the data. They find that for 95% of GERD patients, Newprazole and Omeprazole have identical outcomes. The ICER is infinite or undefinable (Quadrant II – Dominated).
- The Policy Decision: The plan decides it is not cost-effective to pay \$400 for a drug that is no better than an \$8 drug.
- The UM Implementation: They create a Step-Therapy protocol:
- Step 1: Omeprazole (or any generic PPI)
- Step 2: Newprazole
- The Rule: A PA will be required for Newprazole. It will be denied unless the provider can prove the patient has a documented trial and failure OR a contraindication/intolerance to Omeprazole AND one other generic PPI.
This is not a “barrier.” This is a clinically and economically sound policy designed to save the entire health system (and the patient, via lower premiums) millions of dollars by preventing irrational prescribing. Your job is not to fight this logic; it is to work within it.
Visualizing the “Steps”
Most ST protocols are built on a “least expensive, least invasive” to “most expensive, most invasive” logic, which aligns with national clinical guidelines.
Example Step-Therapy Protocol: Type 2 Diabetes (T2DM)
STEP 1: FIRST-LINE THERAPY
Metformin
(Preferred generic, high efficacy, excellent safety, low cost)
IF FAILED (A1c still above goal)
OR CONTRAINDICATED (e.g., eGFR < 30)
STEP 2: SECOND-LINE THERAPY
Sulfonylurea (e.g., Glipizide)
OR TZD (e.g., Pioglitazone)
(Preferred generics, known side effects, low cost)
IF FAILED (A1c still above goal)
OR CONTRAINDICATED (e.g., hypoglycemia risk, CHF)
STEP 3: THIRD-LINE THERAPY (PA REQUIRED)
GLP-1 Agonist (e.g., Ozempic)
OR SGLT2-Inhibitor (e.g., Jardiance)
(Non-preferred brands, high efficacy, cardiovascular benefits, high cost)
The Pharmacist’s Role: The “Step-Therapy Override”
Your job is to get your patient to the correct step, as fast as possible. You are the expert who knows how to use the “elevators” to bypass the stairs. A denial for “Step-Therapy Required” is not a “no.” It is a “yes, if…”. It is a request for documentation. You have two, and only two, ways to win.
The Two “Golden Keys” to a Step-Therapy Override
When you get an ST rejection, you must provide proof of one of these two “keys.”
GOLDEN KEY #1: Documented Trial and Failure
You must prove the patient already took the preferred drug and it didn’t work.
Your Action (The “Pharmacy Detective”):
- Check Your Own Profile: Look at the patient’s fill history in your system. Do you see 6 months of metformin? Bingo.
- Call the Patient: “Hi, Mrs. Jones. Your new insurance wants to know what you’ve tried before for your diabetes. Have you ever taken a medication called metformin?… You did? When was that? And it didn’t work?”
- Call the Old Pharmacy: “Hi, this is [Your Name], a pharmacist at XYZ Specialty. I’m trying to get a new medication covered for our mutual patient, Jane Doe. Her new plan requires a failure of metformin. Could you check your records to see if she filled it with you in the last 12-24 months?”
Your Override Argument: “Patient has a documented trial of Metformin 1000mg BID from 01/2024 to 06/2024 (filled at ABC Pharmacy). A1c on 06/15/2024 was 8.9%, representing a failure of Step 1 therapy. Patient is eligible for Step 2/3.”
GOLDEN KEY #2: Documented Contraindication / Intolerance
You must prove the patient cannot safely take the preferred drug.
Your Action (The “Clinical Investigator”):
- Check the Labs: Pull the patient’s latest lab results. The PA is for a GLP-1 (Step 3). The plan wants a failure of Metformin (Step 1). You look at the labs and see the patient’s eGFR is 25 mL/min. Metformin is contraindicated. This is an “elevator” straight to Step 3.
- Check the Chart/Allergies: The plan wants a failure of a sulfonylurea (Step 2). You see the patient has a documented “Allergy: Sulfa (Anaphylaxis).” Glipizide is a sulfonamide. This is a clear contraindication.
- Check the Chart Notes: The plan wants a failure of Pioglitazone (Step 2). You see in the H&P that the patient has “NYHA Class III Congestive Heart Failure.” TZDs have a black box warning for CHF. This is a clear contraindication.
Your Override Argument: “Patient cannot take Step 1 therapy (Metformin) due to a documented contraindication (eGFR = 25 mL/min as of 10/20/2025). Patient is eligible for Step 3 therapy.”
6.3.4 Deep Dive: Quantity Limits (QLs) — The “Safety Handrail”
Quantity Limits (QLs) are protocols that limit the amount of a drug a plan will cover over a certain period of time. More than any other UM tool, QLs are often driven by patient safety first and cost second.
As a community pharmacist, you are already an expert at these. You see them every day:
- “1 tablet per day” (e.g., 30 tablets per 30-day supply) for statins, PPIs, antidepressants, etc.
- “9 tablets per month” for sumatriptan.
- “2 inhalers per month” for a rescue albuterol inhaler.
- “1 injection per 2 weeks” for a biologic.
The Clinical and Economic Rationale for QLs
QLs serve three distinct purposes:
- 1. To Enforce Clinical Safety (The Primary Goal):
This is the most important and clinically defensible function of a QL. The limit is set to align with established safety guidelines to prevent overuse, abuse, or toxicity.
Example: Triptans (QL = 9 tabs/mo). This is not an arbitrary number. The American Academy of Neurology guidelines for “medication-overuse headache” (MOH) define it as using acute migraine medication on 10 or more days per month. The QL of 9 is a hard-stop safety rail designed to prevent the patient from iatrogenically causing their own rebound headaches.
Example: Opioids (QL = 50 MME/day). This is a direct implementation of CDC guidelines to reduce the risk of respiratory depression and overdose. - 2. To Enforce FDA-Approved Dosing (Cost/Appropriateness):
This is the most common QL. The plan will only pay for the standard, FDA-approved dose.
Example: Omeprazole (QL = 1 cap/day). The standard dose for GERD is 20mg daily. A provider might write for 20mg twice daily. This is “off-label” dosing. The QL rejection is the payer’s way of saying, “We pay for standard dosing. If you want supra-therapeutic dosing, you need to provide a clinical justification (a PA).” This prevents dose “creep” and unnecessary cost. - 3. To Prevent Waste and Stockpiling (Cost):
This prevents patients from refilling maintenance drugs too early, stockpiling, and creating waste (and cost) if the therapy is later changed. It also aligns co-pays and dispensing fees.
Masterclass Table: Navigating Common QL Overrides
Your job is to know why the QL exists so you can build the correct override argument. You must prove that your patient’s situation is clinically exceptional.
| Drug Class | Common QL | Primary Rationale | “Bulletproof” Override Argument |
|---|---|---|---|
| Triptans (e.g., Sumatriptan) |
9 tablets / 30 days | Safety: Prevent Medication-Overuse Headache (MOH) (defined as >10 days/mo). | |
| Opioids (e.g., Oxycodone) |
50 MME / day | Safety: Align with CDC guidelines to reduce overdose risk. | (High Bar to Clear) “Patient has a diagnosis of metastatic breast cancer with bone mets (ICD-10 C79.51) and is under palliative care. The 50 MME safety limit is clinically inappropriate for this patient’s palliative needs. We request an override of the safety QL to manage their documented, intractable cancer pain.” |
| Standard Oral Meds (e.g., PPIs, Statins) |
1 unit / day (30 per 30 days) |
Dosing/Cost: Align with standard FDA-approved dosing. | “Patient has documented, treatment-resistant GERD (ICD-10 K21.0) with erosive esophagitis confirmed by EGD on [Date]. Per ACG guidelines, high-dose PPI (e.g., Omeprazole 20mg BID) is indicated for 8-12 weeks to heal erosions. Standard 1-per-day dosing was ineffective. Please approve 60 tabs / 30 days.” |
| Rescue Inhalers (e.g., Albuterol) |
2 inhalers / 30 days | Safety/Quality: Overuse (>2 canisters/month) is a key indicator of uncontrolled asthma. This QL is a “red flag” to force a clinical re-evaluation. |
The “Safety QL” vs. “Cost QL” Trap
You must recognize the intent of the QL.
If you are trying to override a Cost-Based QL (like for a PPI), your argument is one of efficacy. “The standard dose is not effective.” This is an easy override to win with good documentation.
If you are trying to override a Safety-Based QL (like for an opioid or triptan), your argument must be much stronger. You must prove that you understand the risk and that the patient is an exception (e.g., “palliative care”) or is being monitored for that specific risk (e.g., “neurologist is managing to prevent MOH”). You are not just arguing for efficacy; you are arguing that the benefit outweighs the known risk in this specific, monitored patient.
6.3.5 The Pharmacist’s Ultimate Role: From Adversary to Advocate
In your daily practice, it is easy to become cynical. It is easy to see Utilization Management protocols as purely adversarial. They are frustrating. They delay care. They burn out providers and pharmacists. They are, from one perspective, “barriers.”
An Advanced Specialty Pharmacist, however, must reframe this entire dynamic. You are the only person in the entire healthcare system who stands at the intersection of all stakeholders. You are the expert navigator. These rules are not a “wall” to you; they are a “locked door.” Your new specialty is knowing where the payer hides the “key.”
The “key” is always documentation and clinical justification. Your job is to find it.
This section has given you the blueprints to the entire system. You now understand that these rules are not arbitrary, but are the logical (if frustrating) extension of the economic analyses and safety guidelines that govern modern healthcare. You know why the PA, ST, and QL rules exist. You know what they are designed to accomplish. And now, you have the playbook and the “golden keys” to navigate them.
Your New Mindset and New Scripts
You will now transform your communication from passive and adversarial to proactive and collaborative.
OLD Mindset (Adversarial): “The insurance denied it. It needs a PA. You have to call your doctor.”
NEW Mindset (Proactive Advocate): “The insurance has put a ‘pause’ on this prescription so we can conduct a quick clinical review. This is a normal part of the process for this medication. I’ve already started that review by sending your provider a form with the exact three pieces of information we need to get this approved. I’ll be managing this for you and will call you the moment it’s approved, which we expect in 24-48 hours.”
OLD Mindset (Adversarial): “Your insurance says you have to try the cheap one first. It’s a step-therapy.”
NEW Mindset (Expert Navigator): “The plan’s medical policy, which is based on large-scale effectiveness studies, recommends starting with [Drug X]. This is a great, effective medication. However, I was proactive and checked your profile, and I see you already tried that drug last year and it didn’t work. I am using that fill history right now as ‘proof’ to file for a ‘step-therapy override.’ This is the ‘key’ we need. I am confident the plan will approve this exception, and I’ll let you know when it’s ready.”
This is the pinnacle of the specialty pharmacist’s role. You are no longer just a dispenser of a product. You are a provider of a high-touch, expert service. You create value by absorbing the administrative burden from the patient and the provider. You demonstrate your expertise to the payer by submitting clean, appropriate, and well-documented requests that follow their rules. You are the central hub, the expert guide, and the ultimate patient advocate who aligns the clinical needs of the patient with the economic realities of the system.
